Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Invitrogen™ Human TMEM184B Synthetic Peptide

Catalog No. PEP1046
Change view
Click to view available options
Quantity:
50 μg
1 product options available for selection
Product selection table with 1 available options. Use arrow keys to navigate and Enter or Space to select.
Catalog No. Quantity
PEP1046 50 μg
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 1 options available.
1 options
Catalog No. PEP1046 Supplier Invitrogen™ Supplier No. PEP1046
Add to Cart
Add to Cart

Synthetic Peptide

TMEM184B Synthetic Peptide, PEP-1046, from Invitrogen.

TMEM184B, also known as C22orf5, is a 407 amino acid multi-pass membrane protein and represents a novel gene in the activation of the MAPK signaling pathway. The gene encoding TMEM184B maps to human chromosome 22; mutations in several of the genes in chromosome 22 are involved in the development of autism, schizophrenia, Phelan-McDermid syndrome and Neurofibromatosis type 2, suggesting that TMEM184B may play a role in these syndromes.
TRUSTED_SUSTAINABILITY

Specifications

Gene ID (Entrez) 25829
Species Human
Purification Method purified
Accession Number Q9Y519
Common Name Human TMEM184B
Concentration 200 μg/mL
Content And Storage -20°C
Description Synthetic Peptide
Format Liquid
Formulation PBS with 0.1% BSA and 0.02% sodium azide; pH 7.2
For Use With (Application) Blocking Assay, Control
Gene Symbol TMEM184B
Lyophilized No
Preservative 0.02% sodium azide
Product Type Peptide
Quantity 50 μg
Regulatory Status RUO - research use only
Storage Buffer PBS
Show More Show Less
Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.